254 related articles for article (PubMed ID: 31677966)
1. Novel activators and small-molecule inhibitors of STAT3 in cancer.
Yang L; Lin S; Xu L; Lin J; Zhao C; Huang X
Cytokine Growth Factor Rev; 2019 Oct; 49():10-22. PubMed ID: 31677966
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
3. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening.
Zhang M; Zhu W; Ding N; Zhang W; Li Y
Bioorg Med Chem Lett; 2013 Apr; 23(7):2225-9. PubMed ID: 23434226
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening.
Zhang M; Zhu W; Li Y
Eur J Med Chem; 2013 Apr; 62():301-10. PubMed ID: 23376248
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
Kolosenko I; Yu Y; Busker S; Dyczynski M; Liu J; Haraldsson M; Palm Apergi C; Helleday T; Tamm KP; Page BDG; Grander D
PLoS One; 2017; 12(6):e0178844. PubMed ID: 28636670
[TBL] [Abstract][Full Text] [Related]
7. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors.
Siveen KS; Sikka S; Surana R; Dai X; Zhang J; Kumar AP; Tan BK; Sethi G; Bishayee A
Biochim Biophys Acta; 2014 Apr; 1845(2):136-54. PubMed ID: 24388873
[TBL] [Abstract][Full Text] [Related]
8. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.
Dong J; Cheng XD; Zhang WD; Qin JJ
J Med Chem; 2021 Jul; 64(13):8884-8915. PubMed ID: 34170703
[TBL] [Abstract][Full Text] [Related]
9. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
10. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
11. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells.
Li W; Zhang Q; Chen K; Sima Z; Liu J; Yu Q; Liu J
BMC Complement Altern Med; 2019 Feb; 19(1):38. PubMed ID: 30709346
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.
Mankan AK; Greten FR
Expert Opin Investig Drugs; 2011 Sep; 20(9):1263-75. PubMed ID: 21751940
[TBL] [Abstract][Full Text] [Related]
13. Targeting STAT3 in cancer and autoimmune diseases.
Gharibi T; Babaloo Z; Hosseini A; Abdollahpour-Alitappeh M; Hashemi V; Marofi F; Nejati K; Baradaran B
Eur J Pharmacol; 2020 Jul; 878():173107. PubMed ID: 32278856
[TBL] [Abstract][Full Text] [Related]
14. The role of STAT3 signaling in mediating tumor resistance to cancer therapy.
Tan FH; Putoczki TL; Stylli SS; Luwor RB
Curr Drug Targets; 2014; 15(14):1341-53. PubMed ID: 25410411
[TBL] [Abstract][Full Text] [Related]
15. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature.
Lavecchia A; Di Giovanni C; Cerchia C
Expert Opin Ther Pat; 2014 Apr; 24(4):383-400. PubMed ID: 24432979
[TBL] [Abstract][Full Text] [Related]
16. Identification of small molecule inhibitors of the STAT3 signaling pathway: Insights into their structural features and mode of action.
Kim K; Kim SJ; Han YT; Hong SJ; An H; Chang DJ; Kim T; Lim B; Lee J; Surh YJ; Suh YG
Bioorg Med Chem Lett; 2015 Nov; 25(22):5444-8. PubMed ID: 26392052
[TBL] [Abstract][Full Text] [Related]
17. STAT3: A Potential Drug Target for Tumor and Inflammation.
Hu YS; Han X; Liu XH
Curr Top Med Chem; 2019; 19(15):1305-1317. PubMed ID: 31218960
[TBL] [Abstract][Full Text] [Related]
18. Role of STAT3 in cancer metastasis and translational advances.
Kamran MZ; Patil P; Gude RP
Biomed Res Int; 2013; 2013():421821. PubMed ID: 24199193
[TBL] [Abstract][Full Text] [Related]
19. Cardamonin represses proliferation, invasion, and causes apoptosis through the modulation of signal transducer and activator of transcription 3 pathway in prostate cancer.
Zhang J; Sikka S; Siveen KS; Lee JH; Um JY; Kumar AP; Chinnathambi A; Alharbi SA; Basappa ; Rangappa KS; Sethi G; Ahn KS
Apoptosis; 2017 Jan; 22(1):158-168. PubMed ID: 27900636
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
